Skip to content

INTELLIGENT BIO SOLUTIONS INC.: 10-Q filed 2026-02-12

What INTELLIGENT BIO SOLUTIONS INC. reported in its quarterly report filed 2026-02-12 (fiscal Q2 2026): 43 published measures, 124 facts as tagged in accession 0001493152-26-006311.

This filing

Form
10-Q (quarterly report)
Filed
2026-02-12
Fiscal period
fiscal Q2 2026
Accession
0001493152-26-006311 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All INTELLIGENT BIO SOLUTIONS INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-12-3117,653,042USD
At 2025-06-308,249,786USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-12-316,763,231USD
At 2025-06-305,435,962USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-12-3111,093,132USD
At 2025-06-302,996,136USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-12-31740,371USD
At 2025-06-301,019,909USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-10-01 to 2025-12-31-2,677,590USD92
2025-07-01 to 2025-12-31-5,660,596USD184
2024-10-01 to 2024-12-31-2,249,470USD92
2024-07-01 to 2024-12-31-4,935,103USD184

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-07-01 to 2025-12-31-4,414,340USD184
2024-07-01 to 2024-12-31-4,711,968USD184

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2025-07-01 to 2025-12-31138,633USD184
2024-07-01 to 2024-12-318,936USD184

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2025-10-01 to 2025-12-31896,774USD92
2025-07-01 to 2025-12-312,008,571USD184
2024-10-01 to 2024-12-31607,494USD92
2024-07-01 to 2024-12-311,479,781USD184

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-07-01 to 2025-12-314,232,816USD184
2024-07-01 to 2024-12-31674,194USD184

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2025-07-01 to 2025-12-31-98,475USD184
2024-07-01 to 2024-12-31-8,936USD184

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-12-31-68,193,661USD
At 2025-06-30-62,533,065USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-10-01 to 2025-12-31950,829shares92
2025-07-01 to 2025-12-31902,761shares184
2024-10-01 to 2024-12-31453,582shares92
2024-07-01 to 2024-12-31417,345shares184

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-10-01 to 2025-12-31950,829shares92
2025-07-01 to 2025-12-31902,761shares184
2024-10-01 to 2024-12-31453,582shares92
2024-07-01 to 2024-12-31417,345shares184

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-10-01 to 2025-12-31-2.82USD/shares92
2025-07-01 to 2025-12-31-6.27USD/shares184
2024-10-01 to 2024-12-31-4.96USD/shares92
2024-07-01 to 2024-12-31-11.82USD/shares184

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-10-01 to 2025-12-31-2.82USD/shares92
2025-07-01 to 2025-12-31-6.27USD/shares184
2024-10-01 to 2024-12-31-4.96USD/shares92
2024-07-01 to 2024-12-31-11.82USD/shares184

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2025-12-31321,741USD
At 2025-06-30251,325USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-07-01 to 2025-12-3173,575USD184
2024-07-01 to 2024-12-31214,045USD184

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-10-01 to 2025-12-31-2,635,738USD92
2025-07-01 to 2025-12-31-5,635,331USD184
2024-10-01 to 2024-12-31-2,264,482USD92
2024-07-01 to 2024-12-31-4,989,743USD184

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-12-3112,174,684USD
At 2025-06-304,138,622USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2025-12-315,127,241USD
At 2025-06-305,351,041USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2025-12-313,160,059USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2025-12-31456,657USD
At 2025-06-30594,614USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-10-01 to 2025-12-313,168,197USD92
2025-07-01 to 2025-12-316,879,348USD184
2024-10-01 to 2024-12-312,621,235USD92
2024-07-01 to 2024-12-315,819,425USD184

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2025-12-31590,246USD
At 2025-06-30635,215USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2025-10-01 to 2025-12-31459,739USD92
2025-07-01 to 2025-12-31978,030USD184
2024-10-01 to 2024-12-31223,113USD92
2024-07-01 to 2024-12-31569,914USD184

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2025-10-01 to 2025-12-31437,035USD92
2025-07-01 to 2025-12-311,030,541USD184
2024-10-01 to 2024-12-31384,381USD92
2024-07-01 to 2024-12-31909,867USD184

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2025-10-01 to 2025-12-312,337,041USD92
2025-07-01 to 2025-12-314,996,865USD184
2024-10-01 to 2024-12-311,809,114USD92
2024-07-01 to 2024-12-313,758,130USD184

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-12-311,238,434shares
At 2025-06-30732,326shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-12-3179,540,489USD
At 2025-06-3065,849,823USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2025-12-31-266,079USD
At 2025-06-30-327,944USD

Total equity including noncontrolling interests

Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.

PeriodValueUnitDays
At 2025-12-3110,889,811USD
At 2025-09-303,426,929USD
At 2025-06-302,813,824USD
At 2024-12-314,203,388USD
At 2024-09-305,949,242USD
At 2024-06-308,183,191USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2025-12-311,887,178USD
At 2025-06-3069,520USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2025-08-121,785,294USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2025-12-313,269,439USD
At 2025-06-303,790,319USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2025-10-01 to 2025-12-31-2,686,613USD92
2025-07-01 to 2025-12-31-5,681,605USD184
2025-07-01 to 2025-09-30-2,994,992USD92
2024-10-01 to 2024-12-31-2,256,797USD92
2024-07-01 to 2024-12-31-4,951,596USD184
2024-07-01 to 2024-09-30-2,694,799USD92

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2025-10-01 to 2025-12-31-2,664,441USD92
2025-07-01 to 2025-12-31-5,598,731USD184
2024-10-01 to 2024-12-31-2,392,635USD92
2024-07-01 to 2024-12-31-4,861,913USD184

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2025-07-01 to 2025-12-31585,274USD184
2024-07-01 to 2024-12-31610,746USD184

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2025-10-01 to 2025-12-31212,228USD92
2025-07-01 to 2025-12-31454,597USD184
2024-10-01 to 2024-12-31240,783USD92
2024-07-01 to 2024-12-31476,247USD184

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2025-10-01 to 2025-12-3156,209USD92
2025-07-01 to 2025-12-3160,112USD184
2024-10-01 to 2024-12-3113,502USD92
2024-07-01 to 2024-12-3135,829USD184

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2025-10-01 to 2025-12-31-50,876USD92
2025-07-01 to 2025-12-31-46,274USD184
2024-10-01 to 2024-12-317,685USD92
2024-07-01 to 2024-12-3138,147USD184

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2025-10-01 to 2025-12-31-50,875USD92
2025-07-01 to 2025-12-31-46,274USD184
2024-10-01 to 2024-12-317,685USD92
2024-07-01 to 2024-12-3138,147USD184

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2025-07-01 to 2025-12-31-137,957USD184
2024-07-01 to 2024-12-31-163,624USD184

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2025-07-01 to 2025-12-31-44,969USD184
2024-07-01 to 2024-12-31-76,257USD184

Inspect the source

Entity
INTELLIGENT BIO SOLUTIONS INC. / CIK 0001725430
Captured
2026-09-21T17:27:32.532Z
SEC response SHA-256
853a52aa5d475439c28611414a5b3e3bab760df6971e6f435df2e4acd29b2f46

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001725430.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))